KR20230015333A - 융합된 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물 및 용도 - Google Patents

융합된 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물 및 용도 Download PDF

Info

Publication number
KR20230015333A
KR20230015333A KR1020227039715A KR20227039715A KR20230015333A KR 20230015333 A KR20230015333 A KR 20230015333A KR 1020227039715 A KR1020227039715 A KR 1020227039715A KR 20227039715 A KR20227039715 A KR 20227039715A KR 20230015333 A KR20230015333 A KR 20230015333A
Authority
KR
South Korea
Prior art keywords
alkyl
halogenated
carbocyclyl
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039715A
Other languages
English (en)
Korean (ko)
Inventor
따이구오 덩
구안펑 치어우
용강 왕
쩡롱 레이
Original Assignee
광저우 페르미온 테크놀로지 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 광저우 페르미온 테크놀로지 씨오., 엘티디. filed Critical 광저우 페르미온 테크놀로지 씨오., 엘티디.
Publication of KR20230015333A publication Critical patent/KR20230015333A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227039715A 2020-05-21 2021-05-21 융합된 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물 및 용도 Pending KR20230015333A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010433988 2020-05-21
CN202010433988.6 2020-05-21
CN202110529033 2021-05-14
CN202110529033.5 2021-05-14
PCT/CN2021/095191 WO2021233427A1 (zh) 2020-05-21 2021-05-21 并环化合物及其制备方法、药物组合物和应用

Publications (1)

Publication Number Publication Date
KR20230015333A true KR20230015333A (ko) 2023-01-31

Family

ID=78672734

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039715A Pending KR20230015333A (ko) 2020-05-21 2021-05-21 융합된 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물 및 용도

Country Status (8)

Country Link
US (1) US20230192683A1 (https=)
EP (1) EP4155305A4 (https=)
JP (1) JP7774312B2 (https=)
KR (1) KR20230015333A (https=)
CN (2) CN115991703A (https=)
AU (1) AU2021276301A1 (https=)
TW (1) TWI910166B (https=)
WO (1) WO2021233427A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102023116902A1 (de) 2023-02-06 2024-08-08 Hl Mando Corporation Kolbenventilbaugruppe und stossdämpfer mit dieser baugruppe

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI860849B (zh) 2021-09-14 2024-11-01 美商美國禮來大藥廠 Sstr4促效劑鹽
JP2026509366A (ja) 2023-03-10 2026-03-18 イーライ リリー アンド カンパニー Ｓｓｔｒ４アゴニスト及びその塩の調製のための方法
AU2024236692A1 (en) 2023-03-10 2025-10-16 Eli Lilly And Company Methods for the preparation and dose regimens for use of sstr4 agonists and salts thereof
WO2024245077A1 (zh) * 2023-05-29 2024-12-05 武汉熙瑞医药科技有限公司 3-氮杂-双环[3.1.0]己烷衍生物、其制备方法及其应用
WO2025096300A1 (en) 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
CN120965687A (zh) * 2024-05-17 2025-11-18 广州费米子科技有限责任公司 Sstr4激动剂类化合物的晶体形式及其制备方法和用途
WO2025247982A1 (en) 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2685828A4 (en) * 2011-03-17 2014-08-13 Merck Sharp & Dohme SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS
KR101556318B1 (ko) * 2013-05-15 2015-10-01 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체
US9371282B2 (en) * 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP3045448A4 (en) 2013-09-12 2017-01-25 Sumitomo Chemical Company Limited Nitrogen-containing saturated heterocyclic compound
CN105315293A (zh) * 2014-07-29 2016-02-10 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环化合物及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102023116902A1 (de) 2023-02-06 2024-08-08 Hl Mando Corporation Kolbenventilbaugruppe und stossdämpfer mit dieser baugruppe

Also Published As

Publication number Publication date
CN115991703A (zh) 2023-04-21
WO2021233427A1 (zh) 2021-11-25
JP7774312B2 (ja) 2025-11-21
US20230192683A1 (en) 2023-06-22
EP4155305A4 (en) 2024-07-10
TW202146402A (zh) 2021-12-16
TWI910166B (zh) 2026-01-01
EP4155305A1 (en) 2023-03-29
AU2021276301A1 (en) 2023-01-19
JP2023526791A (ja) 2023-06-23
CN113717167B (zh) 2022-12-02
CN113717167A (zh) 2021-11-30

Similar Documents

Publication Publication Date Title
KR20230015333A (ko) 융합된 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물 및 용도
KR102735310B1 (ko) Nlrp3 인플라마좀 조절제로서의 설포닐 우레아 유도체
CN113929693B (zh) 含氮杂环化合物、药物组合物和应用
EP3781563B1 (en) Hpk1 inhibitors, preparation method and application thereof
CN113717161B (zh) 含氮饱和杂环化合物及其制备方法、药物组合物和应用
CN115835866B (zh) Cereblon结合化合物、其组合物及其用于治疗的方法
TW201840553A (zh) 用於作為shp2抑制劑之新穎雜環衍生物
TW202322811A (zh) Parp-1降解劑及其用途
CN115380036A (zh) Sstr5拮抗剂
TW202128711A (zh) 具有khk抑制作用的化合物
CN119156375A (zh) 双环杂环衍生物和相关用途
WO2024193464A1 (zh) 一种含氮三并环衍生物及其在医药上的应用
TW202225156A (zh) 己酮糖激酶抑制劑及其用途
WO2025103489A1 (zh) 一种hpk1降解剂及其在医药上的应用
KR20260005340A (ko) 트리시클릭 화합물, 이의 제조 방법 및 적용
CN118496202A (zh) 生长抑制素受体亚型4(sstr4)激动剂
WO2019161781A1 (zh) 受体抑制剂、包含其的药物组合物及其用途
JP2025541435A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤及びその応用
HK40062713A (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
CN112778274B (zh) 一种含氮杂环衍生物及其制备
WO2019103897A1 (en) Derivatives of piperlongumine and uses thereof
TWI916367B (zh) 含氮飽和雜環化合物及其製備方法、藥物組合物和應用
HK40062713B (en) Fused-ring compounds, preparation method, pharmaceutical composition and use thereof
CN114478519B (zh) 吡唑并吡啶类化合物或其盐及其制备方法和用途
EP4620950A1 (en) Piperidine derivative, salt of same, and pharmaceutical composition containing same as active ingredient

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000